Get the latest market trends in your inbox
Stay on top of the latest market trends and economic insights with the Axios Markets newsletter. Sign up for free.
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Catch up on coronavirus stories and special reports, curated by Mike Allen everyday
Denver news in your inbox
Catch up on the most important stories affecting your hometown with Axios Denver
Des Moines news in your inbox
Catch up on the most important stories affecting your hometown with Axios Des Moines
Minneapolis-St. Paul news in your inbox
Catch up on the most important stories affecting your hometown with Axios Minneapolis-St. Paul
Tampa-St. Petersburg news in your inbox
Catch up on the most important stories affecting your hometown with Axios Tampa-St. Petersburg
The price of Zynteglo, a new gene therapy made by Bluebird Bio to treat a rare genetic blood disorder, will be almost €1.6 million ($1.8 million) in Europe, the company said Friday.
What's happening: Bluebird expects to get FDA approval for Zynteglo next year and to price it similarly in the U.S., Reuters reports.
The big picture: Zynteglo becomes the second-most expensive drug in the world behind Zolgensma, the $2.1 million gene therapy made by Novartis.
Yes, but: Bluebird will only collect that full price if the treatment is effective in patients after five years, the company said. Health insurers essentially will pay $357,000 per year.
- But it's unclear which entity would be responsible for paying for the treatment if, for example, a patient loses or switches health insurance.
Go deeper: The drug pricing debate is stuck in the past